The present invention aims to provide a method for improving the fluidity of a crystal nucleating agent for polyolefin resins without impairing other properties, and a polyolefin resin composition containing the crystal nucleating agent with improved fluidity and having excellent properties including transparency, and a molded article thereof. Adjustment to specific characteristics can improve the fluidity of a crystal nucleating agent for polyolefin resins, and the use of such a crystal nucleating agent having specific characteristics remarkably improves the workability during molding processing and provides a polyolefin resin composition excellent in properties such as transparency, and a molded article thereof.

A salt of a neuroceutical and of an acid, wherein the neuroceutical is a substituted benzodiazepine, a substituted benzothiazepine, a substituted pyridopyrimidines or a substituted amino-cyclohexaneacetic acid; and the acid is benzoic acid, nicotinic acid, pantothenic acid and tannic acid. The molar ratio of the neuroceutical and the acid in the salt ranges from about 6:1 to about 1:5. Also disclosed herein are compositions comprising the neuroceutical salt and therapeutic uses thereof for treating a central nervous system (CNS) disorder or a metabolic disorder associated with the CNS disorder.

An organic electroluminescence device inducting a cathode, an anode, and an emitting layer disposed between the cathode and the anode, wherein the emitting layer includes a compound represented by the following formula (1) and one or more compounds selected from the group consisting of compounds represented by each of formulas (11), (21), (31), (41), (51), (61), (71) and (81). In the formula (1), at least one of R.sub.1 to R.sub.8 is a deuterium atom,

##STR00001##

An organic electroluminescence device inducting a cathode, an anode, and an emitting layer disposed between the cathode and the anode, wherein the emitting layer includes a compound represented by the following formula (1) and one or more compounds selected from the group consisting of compounds represented by each of formulas (11), (21), (31), (41), (51), (61), (71) and (81). In the formula (1), at least one of R.sub.1 to R.sub.8 is a deuterium atom,

##STR00001##

The present disclosure relates to the field of epoxide synthesis, and particularly to a safe, environmentally friendly and controllable method for preparing cycloaliphatic diepoxides. The method comprises the steps of: mixing a diene compound, a carboxylic acid, an alkaline salt, and a solvent, and cooling; dropwise adding a hydrogen peroxide solution thereto over 1-12 h; standing for layering to obtain an underlayer of an organic phase 1, washing the organic phase 1 with a washing liquid, and standing for layering to obtain an underlayer of an organic phase 2; and purifying the organic phase 2. The reaction system of the present disclosure is simple, environmentally friendly, safe and controllable, and the production cost is low, which can meet the technical and economic requirements. The obtained cycloaliphatic diepoxides have high purity, high yield, low solvent content, low chroma and low halogen content, which are suitable for large-scale industrial production.

The present invention provides methods for the synthesis of ketones involving a Ni/Zr-mediated coupling reaction. The Ni/Zr-mediated ketolization reactions can be used in the synthesis of halichondrins (e.g., halichondrin A, B, C; homohalichondrin A, B, C; norhalichondrin A, B, C), and analogs thereof. Therefore, the present invention also provides synthetic methods useful for the synthesis of halichondrins, and analogs thereof. Also provided herein are compounds (i.e., intermediates) useful in the synthesis of halichondrins, and analogs thereof. In particular, the present invention provides methods and compounds useful in the synthesis of compound of Formula (H3-A). ##STR00001##

The purpose of the present invention is to provide: a π-conjugated compound exhibiting excellent light emission characteristics; an organic electroluminescent element using same; a display device; and an illumination device. Accordingly, this organic electroluminescent element is provided with: a positive electrode; a negative electrode; and at least one organic layer which is sandwiched between the positive electrode and the negative electrode, and which includes a light emission layer. The light emission layer includes a π-conjugated compound having a structure represented by any of general formulae (1)-(3) ##STR00001##
(in general formulae (1)-(3), at least one among R1-R4, R5-R8, and R9-R16 represents a group represented by general formula (4) ##STR00002##
(in general formula (4): Ar1 and Ar2 represent substituted or unsubstituted aryl groups; L1 represents a single bond or a substituted or unsubstituted arylene group; and # represents a bond to general formulae (1)-(3))).

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

The invention provides novel cytotoxic compounds and cytotoxic conjugates comprising these cytotoxic compounds and cell-binding agents. More specifically, this invention relates to novel thailanstatin A analogs, useful as cytotoxic small molecule toxins in antibody-drug conjugates (ADCs). The present invention further relates to compositions including these cytotoxic compounds and ADCs, and methods for using these toxins and ADCs to treat pathological conditions including cancer.

A method of treating a disease that is treatable through inhibition of at least one kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2, TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the method comprising administering an effective dose of a compound represented by the following formula (1) or a salt thereof to a patient: ##STR00001##